论文部分内容阅读
本研究观察了ＩＬ－２联合ＬＡＫ细胞对经病理学证实的４３例恶黑，肾癌，肝癌，肺癌和大肠癌在综合治疗中的作用及其毒副作用。采用ＣＳ－３０００ｐｌｕｓ人体血细胞分离机采集患者自体淋巴细胞，２０万单位ＩＬ－２，肌肉或静脉输注每天１次，每周４次，连续２周；ＬＡＫ细胞（ＩＬ－２浓度为１０００Ｕ／ｍｌ，细胞浓度（２～５）×１０６，３７℃，５％ＣＯ２培养１～２周）每次回输１０亿细胞，第４和第８天回输为一疗程。疗效评价标准采用Ⅲ期临床试验规定标准，结果显示其疗效与病种有关即为恶黑３３％，肾癌１１％，肝癌１０％，肺癌６％；平均总有效率为９％，同时还观察到同一病种内疗效与剂量呈正相关。在治疗中未观察到毒副作用。在ＬＡＫ细胞培养中又观察到经反复治疗的患者其淋巴细胞对ＩＬ－２的反应性增强扩增时间缩短，呈现出免疫反应加快现象，能否说明ＩＬ－２治疗可提高患者免疫力尚需进一步证实。
This study investigated the role of IL-2 combined with LAK cells in pathologically confirmed 43 cases of scurvy, kidney cancer, liver cancer, lung cancer and colorectal cancer in comprehensive treatment and its toxic and side effects. Human autologous lymphocytes were collected using the CS-3000plus human blood cell separator, 200,000 units of IL-2, muscle or intravenous infusion once a day, 4 times per week for 2 weeks; LAK cells (IL-2 concentration 1000 U/ml) , Cell concentration (2 ~ 5) × 106, 37 °C, 5% CO2 cultured for 1 ~ 2 weeks) Each time the return of 1 billion cells, 4 and 8 days back to lose a course of treatment. The efficacy evaluation standard adopts the criteria for phase III clinical trials. The results show that the efficacy is related to disease type: 33% black, 11% kidney cancer, 10% liver cancer, and 6% lung cancer; the average total effective rate is 9%. There was a positive correlation between efficacy and dose to the same disease. No toxic side effects were observed during treatment. In LAK cell culture, the increased reactivity of lymphocytes to IL-2 was observed in patients treated with repeated treatments. The amplification time was shortened, and the immune response was accelerated. Whether IL-2 treatment can improve the patient’s immunity is still needed. Further confirmed.